Welcome to our dedicated page for Eyepoint Pharmac news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on Eyepoint Pharmac stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical innovator advancing sustained-release therapies for retinal diseases through its proprietary Durasert E technology. This page provides investors and industry professionals with a comprehensive repository of official company news, including press releases, clinical trial updates, and strategic developments.
Access timely updates on EYPT’s progress in ocular drug delivery, including regulatory milestones, partnership announcements, and pipeline advancements. Our curated collection ensures you stay informed about critical developments in treatments for wet AMD, diabetic macular edema, and other retinal conditions.
Key updates include progress on DURAVYU™ clinical trials, licensing agreements, financial disclosures, and scientific innovations. All content is sourced directly from company communications to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to EyePoint’s latest developments. Check back regularly for authoritative updates on one of ophthalmology’s most promising sustained-release therapy developers.
EyePoint Pharmaceuticals (EYPT) reported strong progress in Q1 2025, with their Phase 3 DURAVYU trials for wet AMD showing exceptional enrollment rates. The LUGANO trial has reached over 90% enrollment and LUCIA over 50%, with both expected to complete enrollment in 2H 2025. The company reported total net revenue of $24.5 million, up from $11.7 million in Q1 2024, primarily driven by YUTIQ licensing revenue.
The company maintains a strong financial position with $318.2 million in cash and equivalents, providing runway into 2027. Operating expenses increased to $73.3 million, mainly due to accelerated trial enrollment. Net loss was $45.2 million ($0.65 per share). DURAVYU demonstrated promising results in Phase 2 VERONA trial for diabetic macular edema, showing significant vision improvement and fluid reduction compared to aflibercept control.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a pharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 7, 2025.
The company will host a conference call and live webcast at 8:30 a.m. ET to discuss Q1 2025 financial performance and recent corporate developments. Interested participants can register for the audio conference through a provided link, while a live webcast will be accessible through the Investors section of EyePoint's website. A replay of the webcast will be made available on the corporate website after the call concludes.
EyePoint Pharmaceuticals (EYPT) has granted non-statutory stock options to four new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on April 15, 2025, allow the purchase of up to 65,000 shares of EyePoint common stock at an exercise price of $5.67 per share.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint through the applicable dates.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a leading developer of therapeutics for serious retinal diseases, has announced its upcoming participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference.
The company's President and CEO, Jay S. Duker, M.D., will engage in a fireside chat scheduled for April 4, 2025, at 10:00 a.m. ET. Investors and interested parties can access the live webcast and subsequent replay through the Investors section on EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the granting of non-statutory stock options to four new employees as inducement awards. The grants, approved by the Compensation Committee on March 14, 2025, include options to purchase up to 34,500 shares of common stock at an exercise price of $6.52 per share.
The stock options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining amount vesting in equal monthly installments over the following three years. The vesting is contingent upon continued employment with EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 and full-year 2024 financial results, highlighting significant progress in its DURAVYU clinical trials. The LUGANO Phase 3 trial for wet AMD is over 50% enrolled, with both LUGANO and LUCIA trials expected to complete enrollment in H2 2025 and topline data in 2026.
The company reported positive Phase 2 VERONA trial results for DURAVYU in DME, meeting primary and secondary endpoints. Q4 2024 financial results showed total net revenue of $11.6M (down from $14.0M in Q4 2023), with a net loss of $41.4M ($0.64 per share).
Full-year 2024 results included total net revenue of $43.3M (compared to $46.0M in 2023) and a net loss of $130.9M ($2.32 per share). The company maintains a strong financial position with $371M in cash and investments as of December 31, 2024, providing runway into 2027.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a developer of innovative therapeutics for serious retinal diseases, has announced its participation in two major upcoming investor conferences in March 2025.
The company will deliver a corporate presentation at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 4:20 p.m. ET. Additionally, EyePoint will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.
Investors can access live webcasts and archived replays of both presentations through the Investors section of EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has scheduled its fourth quarter and full-year 2024 financial results announcement for March 5, 2025. The company, which focuses on developing innovative therapeutics for serious retinal diseases, will host a conference call and webcast at 8:30 a.m. ET.
Investors and interested parties can access the live conference call through a registration link, while a live audio webcast will be available through the Investors section of EyePoint's website. A replay of the webcast will be accessible on the corporate website after the call concludes.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its President and CEO, Jay S. Duker, M.D., will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th, 2025, at 9:10 a.m. ET.
During the presentation, EyePoint will provide an enrollment update for its ongoing DURAVYU™ Phase 3 pivotal program in wet age-related macular degeneration (wet AMD). Additionally, the company will share additional subgroup analyses from the Phase 2 VERONA clinical trial of DURAVYU in diabetic macular edema (DME).
The presentation will be available via live webcast with an archived replay accessible through the Investors section of EyePoint's website at www.eyepointpharma.com. EyePoint is focused on developing and commercializing innovative therapeutics for patients with serious retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to two new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on February 14, 2025, include options to purchase up to 21,000 shares of common stock at an exercise price of $6.50 per share.
The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting on the first anniversary and the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint Pharmaceuticals.
FAQ
What is the current stock price of Eyepoint Pharmac (EYPT)?
What is the market cap of Eyepoint Pharmac (EYPT)?
